BiotechTube
Home/reMYND/Floor Stam, PhD
FS

Floor Stam, PhD

CEO

reMYND

Therapeutic Areas

Alzheimer's DiseaseHuntington's DiseaseAmyotrophic Lateral Sclerosis (ALS)

reMYND Pipeline

DrugIndicationPhase
REM392 (Alzheimer's Program)Alzheimer's DiseasePre-clinical
Huntington's ProgramHuntington's DiseasePre-clinical
Discovery ProgramAmyotrophic Lateral Sclerosis (ALS)Discovery

Leadership Team at reMYND

GG
Gerard Griffioen, PhD
CSO
CF
Chris Freitag, MD
Clinical Advisor
NV
Nancy Van Osselaer, PhD
Development Advisor
KP
Katrien Princen, PhD
Head of Operations
SL
Sara Lambrechts
Head of Finance
View full reMYND profile